CN105705641B - 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 - Google Patents

涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 Download PDF

Info

Publication number
CN105705641B
CN105705641B CN201480040538.3A CN201480040538A CN105705641B CN 105705641 B CN105705641 B CN 105705641B CN 201480040538 A CN201480040538 A CN 201480040538A CN 105705641 B CN105705641 B CN 105705641B
Authority
CN
China
Prior art keywords
cells
ifn
cytokines
cell
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480040538.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105705641A (zh
Inventor
J·塔威尼尔
J·堡丁克
S·格尔罗
G·尤则
F·保罗
Y·博达特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier filed Critical Universiteit Gent
Priority to CN201911159381.7A priority Critical patent/CN110835376B/zh
Publication of CN105705641A publication Critical patent/CN105705641A/zh
Application granted granted Critical
Publication of CN105705641B publication Critical patent/CN105705641B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201480040538.3A 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 Active CN105705641B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911159381.7A CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306034 2013-07-18
EP13306034.3 2013-07-18
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911159381.7A Division CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Publications (2)

Publication Number Publication Date
CN105705641A CN105705641A (zh) 2016-06-22
CN105705641B true CN105705641B (zh) 2021-07-13

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480040538.3A Active CN105705641B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
CN201911159381.7A Active CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201911159381.7A Active CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Country Status (14)

Country Link
US (3) US10640542B2 (enExample)
EP (2) EP3022305B1 (enExample)
JP (2) JP6580037B2 (enExample)
KR (1) KR102322510B1 (enExample)
CN (2) CN105705641B (enExample)
AU (2) AU2014292371B2 (enExample)
BR (1) BR112016001036B1 (enExample)
CA (1) CA2917937C (enExample)
DK (1) DK3299466T3 (enExample)
ES (2) ES2757501T3 (enExample)
IL (1) IL243451B (enExample)
MX (1) MX375441B (enExample)
SG (2) SG10201808738WA (enExample)
WO (1) WO2015007536A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
EP3454887B1 (en) 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
CN119285770A (zh) 2017-08-09 2025-01-10 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants
WO2022109133A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2024112814A1 (en) * 2022-11-21 2024-05-30 Wisconsin Alumni Research Foundation SYNTHETIC IL6-IL1β FUSION CYTOKINE FOR PROMOTING T CELL CYTOTOXIC FUNCTION, T CELL PROLIFERATION, AND TUMORICIDAL ACTIVITY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632372B2 (en) 1989-08-22 1992-12-24 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
AU778611B2 (en) * 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US7947265B2 (en) * 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
JP2010531666A (ja) 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
KR101661770B1 (ko) 2007-09-21 2016-10-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
US20130115189A1 (en) 2009-09-10 2013-05-09 Cytos Biotechnology Ag Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes
WO2011053991A2 (en) * 2009-11-02 2011-05-05 The Regents Of The University Of California Vault complexes for cytokine delivery
SG10201606680QA (en) * 2009-12-23 2016-10-28 Gradalis Inc Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
CA2796706A1 (en) * 2010-04-22 2011-10-27 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center High affinity leptins and leptin antagonists
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
US9492562B2 (en) * 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
EA037749B1 (ru) * 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Differential responses to IFN-α subtypes in human T cells and dendritic cells;Hilkens CM et al;《The Journal of Immunology》;20031115;第171卷(第10期);5255-5263 *
XCL1 and XCR1 in the immune system;Yu Lei et al;《Microbes and Infection》;20111031;第14卷(第3期);262-267 *

Also Published As

Publication number Publication date
IL243451A0 (en) 2016-03-31
BR112016001036A2 (pt) 2017-10-24
WO2015007536A2 (en) 2015-01-22
WO2015007536A3 (en) 2015-03-19
CN110835376B (zh) 2023-08-04
JP2016525516A (ja) 2016-08-25
JP6853317B2 (ja) 2021-03-31
US20230054612A1 (en) 2023-02-23
US20190010199A1 (en) 2019-01-10
AU2014292371A1 (en) 2016-02-04
AU2014292371B2 (en) 2018-03-29
EP3299466A1 (en) 2018-03-28
MX2016000611A (es) 2016-09-29
AU2018203868A1 (en) 2018-06-21
JP2020002155A (ja) 2020-01-09
BR112016001036B1 (pt) 2023-02-23
ES2757501T3 (es) 2020-04-29
US12410222B2 (en) 2025-09-09
EP3022305A2 (en) 2016-05-25
DK3299466T3 (da) 2019-11-18
CN110835376A (zh) 2020-02-25
JP6580037B2 (ja) 2019-09-25
ES2657060T3 (es) 2018-03-01
KR102322510B1 (ko) 2021-11-08
US11358997B2 (en) 2022-06-14
AU2018203868B2 (en) 2019-12-05
CA2917937A1 (en) 2015-01-22
US10640542B2 (en) 2020-05-05
SG10201808738WA (en) 2018-11-29
CA2917937C (en) 2022-11-01
KR20160108291A (ko) 2016-09-19
CN105705641A (zh) 2016-06-22
HK1252831A1 (en) 2019-06-06
EP3299466B1 (en) 2019-09-11
MX375441B (es) 2025-03-06
EP3022305B1 (en) 2017-11-01
US20180155404A1 (en) 2018-06-07
SG11201600163VA (en) 2016-02-26
IL243451B (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US12410222B2 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
KR102609197B1 (ko) 인터류킨 15 단백질 복합체 및 그의 용도
CN110437339A (zh) 一种以白介素15为活性成分的融合蛋白型药物前体
KR100862136B1 (ko) 인터루킨-18 변이체, 이들의 생산 및 용도
IL184423A (en) Homogeneous preparations of il-31, process for their production and formulations comprising them
CN116096730A (zh) 细胞因子结合物
JP2024543991A (ja) Ｉｌ１０バリアントおよびその使用
Zhan et al. Fusion of HSA influences TNF-α neutralizing activity of shTNFRs
JPH09512165A (ja) インターロイキン１５
HK1252831B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069A1 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
Xiong et al. Cloning and expression of rabbit interleukin-15
US12134635B1 (en) Interleukin 18 (IL-18) variants and fusion proteins comprising same
JP3689111B2 (ja) インターロイキン１５

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Ghent

Applicant after: Univ Gent

Applicant after: Universiteit Gent

Applicant after: Centre National De La Recherche Scientifique

Applicant after: Universite De Montpellier

Applicant after: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

Address before: Ghent

Applicant before: Univ Gent

Applicant before: Universiteit Gent

Applicant before: Centre National De La Recherche Scientifique

Applicant before: Univ. Montpellier II

Applicant before: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

GR01 Patent grant
GR01 Patent grant